Nifty
:
24398.70
Sensex
:
78180.72
-31.65 (-0.13%)
-104.35 (-0.13%)
Nifty
Sensex
:
:
24398.70
78180.72
-31.65 (-0.13%)
-104.35 (-0.13%)

Dr. Reddy's Laboratories Ltd.

Pharmaceuticals & Drugs - Global

Rating :
51/99

BSE: 500124 | NSE: DRREDDY

NSE BSE
1354.60
07-Jul-2026
  • Open
  • High
  • Low
  • Previous Close
  •  1362
  •  1380.2
  •  1351.5
  •  1367.90
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1043736
  •  1419918566.5
  •  1414.9
  •  1148.4

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 1,12,994.24
  • 26.93
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 1,17,379.64
  • 0.59%
  • 2.99

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 26.63%
  • 0.34%
  • 7.57%
  • FII
  • DII
  • Others
  • 21.14%
  • 27.83%
  • 16.49%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 9.03
  • 9.36
  • 6.36

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.07
  • 11.37
  • -4.04

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 12.81
  • 13.97
  • -9.05

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 22.76
  • 19.97
  • 19.10

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.65
  • 3.53
  • 3.36

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.21
  • 13.31
  • 11.78

Earnings Forecasts:

(Updated: 04-07-2026)
Description
2026
2027
2028
2029
Adj EPS
68
-15
2.47
60.9
P/E Ratio
19.92
-90.31
548.42
22.24
Revenue
25.76
21.04
18.24
34360.2
EBITDA
35837.8
39565.9
43371.7
7849.42
Net Income
7391.84
8585.65
9692.71
5091.67
ROA
4391.37
5331.19
6147.48
9.93
P/B Ratio
-0.25
-0.19
-0.15
3.00
ROE
2.71
2.5
2.17
14.24
FCFF
10.96
12.07
12.6
3494.63
FCFF Yield
3962.83
3941.64
4326.44
3.09
Net Debt
3.5
3.48
3.82
-3527.28
BVPS
-5425.61
-7065.14
-9189.36
451.29

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Var%
Dec 25
Dec 24
Var%
Sep 25
Sep 24
Var%
Jun 25
Jun 24
Var%
Net Sales
7,546.40
8,528.40
-11.51%
8,753.40
8,381.20
4.44%
8,828.30
8,038.20
9.83%
8,572.10
7,696.10
11.38%
Expenses
7,163.90
6,530.50
9.70%
6,865.90
6,108.20
12.40%
6,818.40
5,961.70
14.37%
6,398.50
5,566.20
14.95%
EBITDA
382.50
1,997.90
-80.85%
1,887.50
2,273.00
-16.96%
2,009.90
2,076.50
-3.21%
2,173.60
2,129.90
2.05%
EBIDTM
5.07%
23.43%
21.56%
27.12%
22.77%
25.83%
25.36%
27.68%
Other Income
475.40
522.10
-8.94%
268.80
150.20
78.96%
323.90
307.50
5.33%
290.30
187.20
55.07%
Interest
105.70
65.60
61.13%
94.40
81.70
15.54%
90.70
75.70
19.82%
83.00
59.80
38.80%
Depreciation
557.10
454.70
22.52%
521.00
471.40
10.52%
504.60
397.00
27.10%
476.10
380.60
25.09%
PBT
195.10
1,999.70
-90.24%
1,540.90
1,870.10
-17.60%
1,738.50
1,911.30
-9.04%
1,904.80
1,876.70
1.50%
Tax
-21.60
418.50
-
353.60
470.10
-24.78%
408.00
575.50
-29.11%
495.10
490.20
1.00%
PAT
216.70
1,581.20
-86.30%
1,187.30
1,400.00
-15.19%
1,330.50
1,335.80
-0.40%
1,409.70
1,386.50
1.67%
PATM
2.87%
18.54%
13.56%
16.70%
15.07%
16.62%
16.45%
18.02%
EPS
2.65
19.10
-86.13%
14.49
16.95
-14.51%
16.13
15.06
7.10%
16.98
16.70
1.68%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Net Sales
-
33,700.20
32,643.90
28,011.10
24,669.70
21,545.20
19,047.50
17,517.00
15,448.20
14,281.00
14,196.10
Net Sales Growth
-
3.24%
16.54%
13.54%
14.50%
13.11%
8.74%
13.39%
8.17%
0.60%
 
Cost Of Goods Sold
-
12,239.20
9,979.90
8,208.70
7,657.70
7,442.20
6,078.90
5,554.40
4,494.80
4,039.50
3,696.50
Gross Profit
-
21,461.00
22,664.00
19,802.40
17,012.00
14,103.00
12,968.60
11,962.60
10,953.40
10,241.50
10,499.60
GP Margin
-
63.68%
69.43%
70.69%
68.96%
65.46%
68.09%
68.29%
70.90%
71.71%
73.96%
Total Expenditure
-
27,246.70
24,096.80
20,078.00
18,320.70
17,777.80
15,177.60
15,046.60
12,270.00
11,929.80
11,723.90
Power & Fuel Cost
-
556.50
562.50
533.90
477.40
390.50
320.50
314.80
329.10
329.30
330.10
% Of Sales
-
1.65%
1.72%
1.91%
1.94%
1.81%
1.68%
1.80%
2.13%
2.31%
2.33%
Employee Cost
-
5,990.90
5,580.00
5,030.10
4,646.60
3,885.80
3,629.90
3,380.20
3,356.20
3,214.90
3,106.80
% Of Sales
-
17.78%
17.09%
17.96%
18.84%
18.04%
19.06%
19.30%
21.73%
22.51%
21.88%
Manufacturing Exp.
-
2,242.70
2,563.20
2,087.20
1,738.60
1,602.20
1,574.40
1,445.40
1,434.80
1,746.50
1,886.60
% Of Sales
-
6.65%
7.85%
7.45%
7.05%
7.44%
8.27%
8.25%
9.29%
12.23%
13.29%
General & Admin Exp.
-
2,084.40
2,173.20
1,848.20
1,497.50
1,547.60
1,251.80
1,195.20
1,132.10
1,193.40
1,339.90
% Of Sales
-
6.19%
6.66%
6.60%
6.07%
7.18%
6.57%
6.82%
7.33%
8.36%
9.44%
Selling & Distn. Exp.
-
3,597.50
2,925.50
2,248.20
1,989.40
1,919.20
1,567.70
1,408.30
1,423.50
1,330.20
1,293.40
% Of Sales
-
10.68%
8.96%
8.03%
8.06%
8.91%
8.23%
8.04%
9.21%
9.31%
9.11%
Miscellaneous Exp.
-
535.50
312.50
121.70
313.50
990.30
754.40
1,748.30
99.50
76.00
1,293.40
% Of Sales
-
1.59%
0.96%
0.43%
1.27%
4.60%
3.96%
9.98%
0.64%
0.53%
0.50%
EBITDA
-
6,453.50
8,547.10
7,933.10
6,349.00
3,767.40
3,869.90
2,470.40
3,178.20
2,351.20
2,472.20
EBITDA Margin
-
19.15%
26.18%
28.32%
25.74%
17.49%
20.32%
14.10%
20.57%
16.46%
17.41%
Other Income
-
1,358.40
1,097.30
894.30
1,055.50
484.70
291.40
620.60
337.50
155.20
171.50
Interest
-
373.80
282.90
171.10
142.80
95.80
97.00
98.30
88.90
78.80
63.40
Depreciation
-
2,058.80
1,703.70
1,470.00
1,250.20
1,165.20
1,228.80
1,163.10
1,134.80
1,077.20
1,026.60
PBT
-
5,379.30
7,657.80
7,186.30
6,011.50
2,991.10
2,835.50
1,829.60
2,292.00
1,350.40
1,553.70
Tax
-
1,235.10
1,954.30
1,623.10
1,541.20
878.90
931.90
-140.30
385.80
438.00
296.50
Tax Rate
-
22.96%
25.52%
22.59%
25.64%
29.38%
32.87%
-7.67%
16.83%
32.43%
19.08%
PAT
-
4,196.00
5,655.10
5,577.90
4,507.30
2,182.50
1,951.60
2,026.00
1,950.00
912.40
1,257.20
PAT before Minority Interest
-
4,157.60
5,725.20
5,577.90
4,507.30
2,182.50
1,951.60
2,026.00
1,950.00
912.40
1,257.20
Minority Interest
-
38.40
-70.10
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
-
12.45%
17.32%
19.91%
18.27%
10.13%
10.25%
11.57%
12.62%
6.39%
8.86%
PAT Growth
-
-25.80%
1.38%
23.75%
106.52%
11.83%
-3.67%
3.90%
113.72%
-27.43%
 
EPS
-
57.09
76.94
75.89
61.32
29.69
26.55
27.56
26.53
12.41
17.10

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Shareholder's Funds
37,891.50
33,549.60
28,254.80
23,286.10
19,212.40
17,641.70
15,598.80
14,023.60
12,571.60
12,262.10
Share Capital
83.50
83.40
83.40
83.30
83.20
83.20
83.10
83.00
83.00
82.90
Total Reserves
37,659.10
33,321.50
28,040.10
23,057.10
18,985.90
17,431.90
15,411.90
13,861.10
12,406.00
12,098.80
Non-Current Liabilities
926.10
632.90
-36.80
-278.30
-508.30
-197.30
-807.50
2,113.00
2,538.40
456.10
Secured Loans
1,220.30
406.40
219.00
127.80
194.60
249.90
130.40
55.20
63.00
59.70
Unsecured Loans
0.00
380.00
380.00
0.00
380.00
380.00
0.00
2,144.80
2,445.90
485.20
Long Term Provisions
33.80
29.80
23.90
19.90
25.80
50.80
74.50
79.30
81.70
84.20
Current Liabilities
16,747.40
13,033.80
9,588.00
8,572.10
9,765.80
8,103.80
7,214.10
5,897.30
6,893.80
8,419.90
Trade Payables
3,037.90
2,647.80
2,614.40
2,268.40
2,266.20
1,810.90
1,524.80
1,367.10
1,334.50
1,056.90
Other Current Liabilities
6,490.60
5,503.10
4,775.20
4,697.90
3,660.60
3,338.10
3,512.00
2,820.70
2,411.40
2,339.70
Short Term Borrowings
5,913.60
3,804.50
1,272.30
739.00
2,708.20
2,314.50
1,653.20
1,212.50
2,556.20
4,362.60
Short Term Provisions
1,305.30
1,078.40
926.10
866.80
1,130.80
640.30
524.10
497.00
591.70
660.70
Total Liabilities
55,904.40
47,594.10
37,806.00
31,579.90
28,469.90
25,548.20
22,005.40
22,033.90
22,003.80
21,138.10
Net Block
22,063.30
18,226.40
10,425.60
9,219.10
8,121.50
8,205.70
6,850.30
7,191.00
6,968.00
6,930.70
Gross Block
43,854.30
36,759.60
24,527.40
25,567.10
23,096.40
21,886.70
19,335.50
18,048.40
17,436.30
15,932.40
Accumulated Depreciation
21,494.10
18,533.20
14,101.30
16,348.00
14,894.90
13,632.10
12,485.20
10,857.40
10,468.30
9,001.70
Non Current Assets
25,875.60
22,576.10
13,000.70
11,154.50
10,682.00
10,997.90
9,406.30
10,923.80
11,505.40
11,454.40
Capital Work in Progress
1,460.20
2,465.60
1,419.30
1,030.10
1,293.40
1,565.10
1,535.10
2,933.50
3,470.50
3,324.50
Non Current Investment
1,612.00
720.50
525.50
536.30
593.00
833.30
309.10
334.20
465.30
682.60
Long Term Loans & Adv.
506.60
341.40
541.80
355.90
451.70
377.00
688.70
426.70
564.80
482.10
Other Non Current Assets
233.50
822.20
88.50
13.10
222.40
16.80
23.10
38.40
36.80
34.50
Current Assets
30,028.80
25,018.00
24,805.30
20,425.40
17,787.90
14,535.20
12,599.10
11,110.10
10,498.40
9,683.70
Current Investments
3,672.80
3,330.60
4,405.00
4,449.50
2,022.90
1,378.50
2,368.70
2,252.90
1,833.00
1,427.10
Inventories
7,653.40
7,108.50
6,355.20
4,867.00
5,088.40
4,541.20
3,506.70
3,357.90
2,908.90
2,852.80
Sundry Debtors
10,123.40
9,042.00
8,029.80
7,248.50
6,676.40
4,964.10
5,027.80
3,986.90
4,052.70
3,798.60
Cash & Bank
3,348.70
2,460.20
1,727.70
1,730.20
2,419.20
2,078.80
205.30
222.80
263.80
386.50
Other Current Assets
5,230.50
1,072.40
1,011.30
1,203.50
1,581.00
1,572.60
1,490.60
1,289.60
1,440.00
1,218.70
Short Term Loans & Adv.
4,047.10
2,004.30
3,276.30
926.70
844.10
722.70
444.50
439.80
674.10
767.20
Net Current Assets
13,281.40
11,984.20
15,217.30
11,853.30
8,022.10
6,431.40
5,385.00
5,212.80
3,604.60
1,263.80
Total Assets
55,904.40
47,594.10
37,806.00
31,579.90
28,469.90
25,533.10
22,005.40
22,033.90
22,003.80
21,138.10

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Cash From Operating Activity
5,673.70
4,642.80
4,543.30
5,887.50
2,810.80
3,570.30
2,984.10
2,870.40
1,803.00
2,144.40
PBT
5,392.70
7,679.50
7,201.00
6,048.50
3,061.40
2,883.50
1,885.70
2,335.80
1,350.40
1,553.70
Adjustment
2,708.20
1,961.50
1,365.20
1,695.90
2,333.80
2,087.20
2,562.50
835.00
1,625.30
1,687.30
Changes in Working Capital
-1,074.60
-2,998.90
-2,018.20
-785.50
-1,840.70
-828.80
-753.60
183.70
-896.60
-519.60
Cash after chg. in Working capital
7,026.30
6,642.10
6,548.00
6,958.90
3,554.50
4,141.90
3,694.60
3,354.50
2,079.10
2,721.40
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1,352.60
-1,999.30
-2,004.70
-1,071.40
-743.70
-571.60
-710.50
-484.10
-276.10
-577.00
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-6,549.30
-5,807.70
-4,028.30
-4,137.30
-2,638.70
-2,266.00
-492.30
-772.70
-1,488.30
-1,840.40
Net Fixed Assets
-2,801.90
-2,403.40
-1,447.20
-1,511.60
-1,303.60
-2,618.10
-453.50
-275.60
-683.20
-1,019.30
Net Investments
-2,401.30
-5,872.90
119.40
-2,503.30
-287.50
836.30
-1,552.00
-297.00
-534.60
1,974.20
Others
-1,346.10
2,468.60
-2,700.50
-122.40
-1,047.60
-484.20
1,513.20
-200.10
-270.50
-2,795.30
Cash from Financing Activity
829.00
1,891.10
-376.30
-2,686.10
-242.20
-29.80
-2,515.90
-2,132.60
-444.00
-369.20
Net Cash Inflow / Outflow
-46.60
726.20
138.70
-935.90
-70.10
1,274.50
-24.10
-34.90
-129.30
-65.20
Opening Cash & Equivalents
1,459.30
710.70
577.90
1,485.20
1,482.00
196.20
222.80
254.20
377.80
492.10
Closing Cash & Equivalent
1,536.80
1,459.30
710.70
577.90
1,485.20
1,482.00
196.20
222.80
254.20
377.80

Financial Ratios

Consolidated /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Book Value (Rs.)
452.01
400.54
337.21
277.80
1145.98
1052.59
932.31
840.01
752.35
734.72
ROA
8.03%
13.41%
16.08%
15.01%
8.08%
8.01%
8.95%
8.66%
4.23%
6.14%
ROE
11.69%
18.61%
21.76%
21.36%
11.93%
11.53%
13.38%
14.42%
7.40%
10.20%
ROCE
13.75%
23.25%
26.86%
26.22%
14.59%
15.24%
10.81%
13.41%
8.21%
9.77%
Fixed Asset Turnover
0.84
1.07
1.12
1.01
0.96
0.92
0.94
0.87
0.86
0.92
Receivable days
103.79
95.44
99.54
103.01
98.60
95.74
93.92
94.98
100.33
101.86
Inventory Days
79.94
75.27
73.12
73.65
81.57
77.11
71.52
74.03
73.63
69.56
Payable days
84.78
96.23
108.56
108.07
99.98
100.14
39.56
39.46
37.10
31.00
Cash Conversion Cycle
98.95
74.48
64.10
68.59
80.19
72.70
125.88
129.55
136.86
140.42
Total Debt/Equity
0.20
0.14
0.07
0.06
0.18
0.17
0.14
0.28
0.41
0.40
Interest Cover
15.43
28.15
43.09
43.36
32.96
30.23
19.61
26.78
18.14
25.51

Annual Reports:

FY 2026
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017

News Update:


  • Dr. Reddy’s launches Bosutinib Tablets 400mg in US
    13th Jun 2026, 15:57 PM

    Dr. Reddy’s has collaborated with MSN Laboratories on this product

    Read More
  • Dr. Reddy's Laboratories launches generic Semaglutide Injection in Canada
    16th May 2026, 11:47 AM

    The company’s Semaglutide Injection is indicated for the once-weekly treatment of adults with type 2 diabetes mellitus

    Read More
  • Dr. Reddy's Laboratories reports 86% plunge in Q4FY26 consolidated net profit
    13th May 2026, 12:12 PM

    Consolidated total income of the company decreased by 11.37% at Rs 8,021.80 crore for Q4FY26

    Read More
  • Dr. Reddy's Lab - Quarterly Results
    13th May 2026, 00:00 AM

    Read More
  • Dr. Reddy's Lab gets Health Canada’s nod for Generic Semaglutide Injection
    29th Apr 2026, 10:51 AM

    The company becomes the first company to receive the market authorization for generic Semaglutide Injection in Canada

    Read More
  • Dr. Reddy's Laboratories to sell entire shareholding in Svaas Wellness
    8th Apr 2026, 16:00 PM

    Consequent to the completion of the transaction, Svaas Wellness will cease to be a wholly owned subsidiary of the Company

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.